Aurinia Pharmaceuticals Inc AUPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
-
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
-
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
-
Aurinia Announces Management Transition
Trading Information
- Previous Close Price
- $16.37
- Day Range
- $15.82–16.70
- 52-Week Range
- $7.29–16.88
- Bid/Ask
- $15.80 / $16.05
- Shares Outstanding
- 128.60M
- Market Cap
- $2.04B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 7.16
- Price/Sales
- 7.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 4.29%
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 128
- Website
- https://www.auriniapharma.com
Valuation
|
Metric
|
AUPH
|
|---|---|
Price/Earnings (Normalized) | 7.16 |
Price/Book Value | 3.65 |
Price/Sales | 7.29 |
Price/Cash Flow | 13.29 |
Price/Earnings
AUPH
Financial Strength
|
Metric
|
AUPH
|
|---|---|
Quick Ratio | 4.94 |
Current Ratio | 5.55 |
Interest Coverage | 29.12 |
Quick Ratio
AUPH
Profitability
|
Metric
|
AUPH
|
|---|---|
Return on Assets (Normalized) | 53.03% |
Return on Equity (Normalized) | 72.56% |
Return on Invested Capital (Normalized) | 60.32% |
Return on Assets
AUPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Fwxqntlft | Yjhllf | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ntybvkvm | Pgtqkg | $67B | |||
| argenx SE ADR
ARGX
| Czkzwmmt | Crxc | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pwbqncvg | Kjwmhv | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Plbmtfzrj | Pmpnrp | $25B | |||
| BioNTech SE ADR
BNTX
| Pcqqqhvh | Vpnx | $22B | |||
| Incyte Corp
INCY
| Rszbbgfk | Jmgk | $20B | |||
| Moderna Inc
MRNA
| Dyvlsxl | Hrj | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Chztxfc | Vqnst | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Hwyyffwpq | Vdx | $13B |
United States